HCW Biologics Inc.
HCWB
$7.05
-$0.58-7.60%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 394.80K | 426.40K | 618.90K | 1.13M | 1.32M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 394.80K | 426.40K | 618.90K | 1.13M | 1.32M |
| Cost of Revenue | 315.80K | 341.10K | 438.40K | 512.00K | 1.07M |
| Gross Profit | 79.00K | 85.30K | 180.40K | 614.70K | 252.60K |
| SG&A Expenses | 3.52M | 2.61M | 12.01M | 6.01M | 8.91M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.85M | 4.12M | 14.45M | 8.62M | 12.09M |
| Operating Income | -4.46M | -3.69M | -13.84M | -7.49M | -10.77M |
| Income Before Tax | -3.37M | -3.90M | -15.28M | -7.47M | -10.68M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.37M | -3.90M | -15.28M | -7.47M | -10.68M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.37M | -3.90M | -15.28M | -7.47M | -10.68M |
| EBIT | -4.46M | -3.69M | -13.84M | -7.49M | -10.77M |
| EBITDA | -3.78M | -3.56M | -13.71M | -7.25M | -10.49M |
| EPS Basic | -3.19 | -4.13 | -16.16 | -8.03 | -11.87 |
| Normalized Basic EPS | -2.76 | -2.58 | -9.24 | -5.02 | -7.42 |
| EPS Diluted | -3.19 | -4.13 | -16.16 | -8.03 | -11.87 |
| Normalized Diluted EPS | -2.76 | -2.58 | -9.24 | -5.02 | -7.42 |
| Average Basic Shares Outstanding | 1.06M | 945.60K | 945.60K | 930.60K | 899.90K |
| Average Diluted Shares Outstanding | 1.06M | 945.60K | 945.60K | 930.60K | 899.90K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |